Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...

Peptic Ulcer Disease IV: Management

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...

Gastroesophageal Reflux Disease II: Clinical Features and Management

Gastroesophageal Reflux Disease II: Clinical Features and Management

Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...

Modified-Release Drug Delivery Systems: Bioavailability

Modified-Release Drug Delivery Systems: Bioavailability

Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...

Modified-Release Drug Delivery Systems: Overview

Modified-Release Drug Delivery Systems: Overview

Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A national consensus guideline on the performance and interpretation of hydrogen- and methane-based breath tests for carbohydrate malabsorption, small intestinal bacterial overgrowth, and intestinal methanogen overgrowth.

Annals of gastroenterology·2026

Same author

Potassium-competitive acid blockers and proton-pump inhibitors for the healing and maintenance of erosive esophagitis: a comprehensive and updated systematic review with network meta-analysis.

Esophagus : official journal of the Japan Esophageal Society·2026

Same author

Short-Term Daily Vonoprazan Treatment Is More Commonly Associated With Infectious Gastroenteritis Than Short-Term Daily PPI Treatment.

Neurogastroenterology and motility·2026

Same author

Lyon Consensus 2.0: what has changed for GERD diagnosis?

Expert review of gastroenterology & hepatology·2026

Same author

Trends in Utilization of Surgical and Endoscopic Anti-Reflux Procedures in the United States (1995-2024).

Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society·2026

Same author

Pandemic-Related Disruptions and Hepatocellular Carcinoma Surveillance in Safety-Net Settings.

JAMA network open·2026

Search research articles

Related Experiment Videos

Dexlansoprazole MR: a review.

Tiberiu Hershcovici¹, Lokesh K Jha, Ronnie Fass

¹Neuroenteric Clinical Research Group, Southern Arizona VA Health Care System, Tucson, USA.

Annals of Medicine

|March 4, 2011

Summary

Dexlansoprazole MR, a dual delayed-release proton pump inhibitor, effectively heals erosive esophagitis and controls symptoms in GERD patients. It offers higher maintenance rates and can be taken without regard to food, with a well-tolerated side-effect profile.

Area of Science:

Gastroenterology
Pharmacology
Drug Delivery Systems

Background:

Proton pump inhibitors (PPIs) are mainstays in treating gastroesophageal reflux disease (GERD).
Dexlansoprazole MR represents an advancement in PPI delivery through its dual delayed-release formulation.
Previous studies established the efficacy of lansoprazole in managing acid-related disorders.

Purpose of the Study:

To evaluate the efficacy of dexlansoprazole MR in healing erosive esophagitis compared to lansoprazole.
To assess the maintenance of healed esophageal mucosa and symptom control in patients with GERD.
To determine the impact of food intake on dexlansoprazole MR efficacy and tolerability.

Main Methods:

Comparative clinical trials were conducted to assess dexlansoprazole MR against lansoprazole and placebo.

Related Experiment Videos

Patient outcomes included healing rates of erosive esophagitis and maintenance of esophageal mucosa.

Symptom control in non-erosive reflux disease (NERD) was evaluated.

Pharmacokinetic studies assessed dexlansoprazole MR absorption with and without food.

Main Results:

Dexlansoprazole MR demonstrated efficacy in healing erosive esophagitis, comparable to lansoprazole.
Significantly higher maintenance rates for healed esophageal mucosa were observed with dexlansoprazole MR versus placebo.
Dexlansoprazole MR provided significant symptom control in patients with non-erosive reflux disease.
The drug can be administered without regard to food, offering dosing flexibility.

Conclusions:

Dexlansoprazole MR is an effective treatment for erosive esophagitis and GERD symptoms.
The dual delayed-release formulation enhances drug delivery and patient convenience.
Dexlansoprazole MR is well-tolerated with a side-effect profile similar to lansoprazole.